Amgen Breaks Barriers: Repatha Cholesterol Drug Now Direct to Patients at 60% Off
This week marks a turning point in the fight for affordable medication, with pharmaceutical giant Amgen announcing the launch of AmgenNow, a direct-to-patient program slashing the cost of Repatha by nearly 60%. Conservative voters, policy wonks, and Americans tired of Big Pharma’s old ways should sit up and take note—this dramatic price cut reflects President Donald Trump’s (R) leadership and ongoing campaign to force drug companies to put American families first.
Repatha, an injectable cholesterol medication that has been on the market since 2015, will now be available for just $239 per month to eligible U.S. patients—significantly below its former list price. The new program, AmgenNow, opens direct access to anyone in need, even those who are uninsured or have high-deductible plans. Amgen’s announcement makes Repatha the latest in a line of essential drugs now available outside the grasp of insurance red tape. Amgen launched AmgenNow, a direct-to-patient program offering Repatha at $239 per month, nearly 60% below its current U.S. list price.
More importantly, Amgen’s move didn’t come out of the blue. The decision clearly follows President Trump’s repeated calls for pharmaceutical companies to end price gouging and compete with the prices found in other developed nations. The president’s stance forced Big Pharma to rethink its American pricing model—an effort finally paying off at the kitchen table for millions. As Americans struggle with healthcare costs, conservatives have long pushed for free-market answers like this direct-to-patient approach rather than more government interference or single-payer schemes that never deliver on their promises.
“It’s about time Americans get a fair deal. Trump made it clear: Put American consumers first—not insurance companies or middlemen,” said policy analyst Dan Rivers at the American Center for Medical Reform.
Alongside the AmgenNow program, online healthcare platform GoodRx said it will match the new $239 cash price and offer Repatha at over 70,000 pharmacies coast to coast, making the breakthrough even more widely available. For too long, drug-pricing cartels and regulatory hurdles have kept prices artificially high, punishing hard-working citizens. With market-based solutions finally getting traction, Americans can look forward to a new era of choice and competition.
The fact that this drastic price drop came so soon after months of pro-consumer pressure from the White House is no accident. The Trump administration’s planned launch of the TrumpRx website in 2026, where Americans can buy drugs directly from manufacturers, has sent shockwaves through the health industry.
Main Narrative: Affordable Cholesterol Medication Brings Real Relief for Americans
For years, patients in need of cholesterol medication have faced bureaucratic obstacles, insane prices, and insurance headaches. Repatha—a medicine backed by solid research and widely used worldwide—has often been financially out of reach, especially for the uninsured or those struggling to meet deductibles. The AmgenNow program is open to all U.S. patients, including those who are uninsured, in high-deductible health plans, or prefer to pay with cash or out-of-pocket. (Amgen)
That era may finally be ending. According to Amgen’s Monday press release, Repatha will now be available at a rock-bottom price, enabling patients to bypass insurance companies and excessive markups. The innovation doesn’t stop there; AmgenNow gives patients clear information and support, maximizing their health journey while minimizing administrative hoops.
Market-watchers noted Amgen’s stock price declined after the announcement as Wall Street absorbed the company’s pivot toward patient-first business. But for everyday citizens, the win is obvious: increased access and dramatically lower prices. Conservative lawmakers and Trump administration officials have long said that transparency and free-market reforms—not government rationing or mandates—would drive down drug prices and expand access. This news could be a template for future patient-driven drug reforms.
“Instead of endless forms and weeks of uncertainty, AmgenNow means patients with cholesterol risks can get started with the therapy their doctors recommend—fast. It’s a remarkable change that will save lives and reduce heart disease,” noted Dr. Katherine Rollins, a Florida-based cardiologist and Trump supporter.
This program’s launch adds to Amgen’s growing U.S. footprint, coming on the heels of a $650 million domestic manufacturing expansion and additional investments in biopharmaceutical innovation nationwide. As American manufacturers bring jobs and critical industries home, President Trump’s policies continue to push U.S. companies to invest here, not abroad. These homegrown jobs and medical advances reinforce a key tenet of the Trump movement: American solutions, for American problems.
Consumers are also benefiting thanks to rising pressure across the sector. GoodRx’s partnership, making the $239 cash price available at over 70,000 U.S. pharmacies, means competitors will have little excuse for gouging customers. Americans are demanding that prices be set by the marketplace, not by bureaucrats or monopoly pricing boards. The success of this approach will no doubt spark a domino effect in other areas of medicine where red tape and government failure have kept costs high.
It’s not just a win for conservative healthcare reform. Liberals have long argued for expanded regulation or outright government takeovers to control drug costs, but those plans have repeatedly ended in bureaucracy and delay. This direct-to-patient solution provides a live example: when drug makers respond to tough negotiations led by an America First president, patients win—quickly and clearly.
Trump’s Pro-Consumer Pressure: Background, Impact, and What’s Next
Americans have waited decades for relief from astronomical drug prices. From the start of his presidency, Donald Trump (R) made lowering prescription costs a priority. After forcing the hand of Big Pharma with his America First trade negotiations, he demanded that companies charge Americans the same price they charge developed nations overseas. That push set off a chain reaction, and Amgen’s latest move proves it’s working.
The Trump administration’s plan to launch the TrumpRx website in early 2026 will further empower consumers. Patients will be able to bypass insurance middlemen altogether, searching for—and buying—medication directly from manufacturers. This approach tears down the bureaucratic roadblocks that have plagued the American healthcare system for generations.
“We don’t need more paperwork, rationing, or waiting. Trump’s vision for healthcare is simple: give Americans transparency, choice, and control—without raising taxes or expanding government,” said former HHS official Lisa Carrington (R).
The AmgenNow initiative stands in stark contrast to government-run attempts that have repeatedly left patients stuck in lines or mired in paperwork. With private investment growing—like Amgen’s $650 million expansion to domestic manufacturing and additional billion-dollar investments across Ohio, North Carolina, and California—American workers benefit, and vital new treatments move from labs to pharmacy shelves faster.
Market signals remain clear. Even after a brief downturn, Amgen has invested nearly $3 billion in new American facilities since 2022—evidence that fair pricing and American leadership can coexist with corporate profitability. Conservatives have proven that tough negotiations and an America First agenda drive competition, investment, and consumer value.
The broader implications can’t be overstated. As other drug companies see consumers embracing these models, competitive forces will do what bureaucratic mandates never could: lower costs, widen access, and restore American leadership in healthcare innovation. If Trump and a conservative Congress continue making these consumer-first policies law, more patients will soon see savings on everything from asthma inhalers to cancer drugs.
The message for 2025 and beyond? Market-driven reform, not government control, is the answer. The Trump administration’s legacy is clear: putting American patients and taxpayers at the center of the healthcare system, and forcing the powerful to serve the people once again.